CR10072A - Derivados de pirimidinil-aril-urea que son inhibidores de fgf - Google Patents

Derivados de pirimidinil-aril-urea que son inhibidores de fgf

Info

Publication number
CR10072A
CR10072A CR10072A CR10072A CR10072A CR 10072 A CR10072 A CR 10072A CR 10072 A CR10072 A CR 10072A CR 10072 A CR10072 A CR 10072A CR 10072 A CR10072 A CR 10072A
Authority
CR
Costa Rica
Prior art keywords
pirimidinil
aril
urea derivatives
heteroaryl
fgf inhibitors
Prior art date
Application number
CR10072A
Other languages
English (en)
Inventor
Bold Guido
Furet Pascal
Guagnano Vito
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR10072A publication Critical patent/CR10072A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a heteroaril-aril-ureas de la Fórmula (IA), en donde los radicales y símbolos tienen los significados definidos en la presente, al uso de estos compuestos en el tratamiento de enfermedades dependientes de cinasa de proteína; a preparaciones farmacéuticas que comprenden estas heteroaril-aril-ureas; a procesos para la fabricación de estos compuestos novedosos, y a métodos de tratamiento que comprenden el uso de estas heteroaril-aril-ureas.
CR10072A 2005-12-21 2008-06-13 Derivados de pirimidinil-aril-urea que son inhibidores de fgf CR10072A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75271105P 2005-12-21 2005-12-21

Publications (1)

Publication Number Publication Date
CR10072A true CR10072A (es) 2008-08-25

Family

ID=37946774

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10072A CR10072A (es) 2005-12-21 2008-06-13 Derivados de pirimidinil-aril-urea que son inhibidores de fgf

Country Status (22)

Country Link
US (2) US8293746B2 (es)
EP (1) EP1976847B1 (es)
JP (1) JP5153645B2 (es)
KR (1) KR101406956B1 (es)
CN (1) CN101336237B (es)
AU (1) AU2006326989B2 (es)
BR (1) BRPI0620408B8 (es)
CA (1) CA2634047C (es)
CR (1) CR10072A (es)
EA (1) EA016438B1 (es)
EC (1) ECSP088561A (es)
GE (1) GEP20105074B (es)
HN (1) HN2008000949A (es)
IL (1) IL192093A0 (es)
MA (1) MA30063B1 (es)
ME (2) MEP3808A (es)
NO (1) NO20083214L (es)
SM (1) SMP200800041B (es)
SV (1) SV2008002967A (es)
TN (1) TNSN08276A1 (es)
WO (1) WO2007071752A2 (es)
ZA (1) ZA200805092B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2007071752A2 (en) * 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
CN102666498A (zh) * 2009-08-28 2012-09-12 健泰科生物技术公司 Raf抑制剂化合物及其使用方法
ES2524548T3 (es) * 2009-10-30 2014-12-10 Novartis Ag N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
US20120258940A1 (en) * 2009-12-18 2012-10-11 Giordano Caponigro Method for treating haematological cancers
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
UA114501C2 (uk) 2012-02-28 2017-06-26 Астеллас Фарма Інк. Азотовмісна ароматична гетероциклічна сполука
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
MX2015002959A (es) * 2013-03-10 2015-06-05 Univ Nagoya Nat Univ Corp Agente terapeutico para padecimiento sistemico oseo y uso del mismo.
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2968551B1 (en) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
JP6576325B2 (ja) 2013-03-15 2019-09-18 セルジーン シーエーアール エルエルシー ヘテロアリール化合物およびそれらの使用
EP2789619A1 (en) 2013-04-12 2014-10-15 Kemotech S.r.l. Pharmaceutical compounds wiht angiogenesis inbhibitory activity
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
AU2014287209B2 (en) * 2013-07-09 2019-01-24 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
SMT201800379T1 (it) 2013-10-18 2018-09-13 Eisai R&D Man Co Ltd Inibitori di fgfr4 della pirimidina
BR112016008276B1 (pt) * 2013-10-25 2021-03-02 Novartis Ag derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica
CN105813635A (zh) 2013-12-13 2016-07-27 诺华股份有限公司 药物剂型
US10287268B2 (en) 2014-07-21 2019-05-14 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
DK3172213T3 (da) 2014-07-21 2021-12-13 Dana Farber Cancer Inst Inc Makrocykliske kinasehæmmere og anvendelser deraf
WO2016023014A2 (en) * 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
MX369646B (es) 2014-08-18 2019-11-15 Eisai R&D Man Co Ltd Sal de derivado de piridina monociclico y su cristal.
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3237452A4 (en) 2014-12-23 2018-12-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
AU2016237222B2 (en) 2015-03-25 2021-04-29 Eisai R&D Management Co., Ltd. Therapeutic agent for bile duct cancer
CN107660200B (zh) 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
CN104803925B (zh) * 2015-04-16 2018-01-12 温州医科大学 一类以fgfr为靶点的2，4，5‑三取代嘧啶类化合物及其制备方法和用途
US10624897B2 (en) 2015-07-20 2020-04-21 Taipei Medical University Chlorobenzene substituted azaaryl compounds
CA3001969C (en) 2015-12-17 2023-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
US10934311B2 (en) * 2016-01-08 2021-03-02 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic compound used as FGFR inhibitor
EP3454898B1 (en) 2016-05-10 2021-11-10 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation
AU2017291812B2 (en) 2016-07-05 2023-12-14 Dana-Farber Cancer Institute, Inc. Bicyclic urea kinase inhibitors and uses thereof
US11241435B2 (en) 2016-09-16 2022-02-08 The General Hospital Corporation Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis
HUE063405T2 (hu) * 2016-12-19 2024-01-28 Epizyme Inc Amin-szubsztituált heterociklusos vegyületek, mint EHMT2 inhibitorok és felhasználásuk módszerei
BR112019017741A2 (pt) 2017-02-28 2020-04-07 Dana Farber Cancer Inst Inc usos de pirimidopirimidinonas como inibidores de sik
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JPWO2019189241A1 (ja) 2018-03-28 2021-03-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌治療剤
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
CN109053594B (zh) * 2018-08-07 2020-12-18 温州医科大学 1-(3,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN109053593B (zh) * 2018-08-07 2020-12-04 温州医科大学 1-(2,6-氯苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
CN109053592B (zh) * 2018-08-07 2020-12-04 温州医科大学 1-(2,5-二甲氧基苯基)-3-(取代嘧啶-4-基)脲类化合物及其制备和应用
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
CN110283130B (zh) * 2019-07-05 2023-12-19 温州医科大学 一种1-(2,5-二甲氧基苯基)-3-取代脲类结肠癌抑制剂及其制备和应用
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2025090870A1 (en) * 2023-10-27 2025-05-01 Qed Therapeutics, Inc. Infigratinib and metabolites thereof for use in methods of treating skeletal disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759921A (en) * 1969-10-16 1973-09-18 Lilly Co Eli Method of suppressing immuneresponse with 1 substituted-3-(2 pyrimidyl)ureas
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
EP1415987B1 (en) * 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
ITMI20010528A1 (it) 2001-03-13 2002-09-13 Istituto Biochimico Pavese Pha Complessi di resveratrolo con fosfolipidi loro preparazione e composizioni farmaceutiche e cosmetiche
US20020156257A1 (en) 2001-03-29 2002-10-24 Chunhua Yan Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof
GB0201508D0 (en) * 2002-01-23 2002-03-13 Novartis Ag Organic compounds
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
US7125997B2 (en) 2002-12-20 2006-10-24 Irm Llc Differential tumor cytotoxicity compounds and compositions
WO2005030735A1 (en) 2003-09-25 2005-04-07 Ranbaxy Laboratories Limited Triazines derivatives as cell adhesion inhibitors
TW200529849A (en) 2003-11-28 2005-09-16 Novartis Ag Diaryl urea derivatives in the treatment of protein kinase dependent diseases
EP1753750A1 (en) 2004-05-20 2007-02-21 Sugen, Inc. Thiophene heteroaryl amines
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
CA2619366A1 (en) 2005-08-22 2007-03-01 Amgen Inc. Bis-aryl urea compounds for the treatment of protein kinase-mediated diseases
WO2007071752A2 (en) * 2005-12-21 2007-06-28 Novartis Ag Pyrimidinyl aryl urea derivatives being fgf inhibitors
US20090062320A1 (en) * 2007-08-28 2009-03-05 Vito Guagnano Method of Treating Disorders Mediated by the Fibroblast Growth Factor Receptor

Also Published As

Publication number Publication date
US8293746B2 (en) 2012-10-23
KR101406956B1 (ko) 2014-06-13
US8759517B2 (en) 2014-06-24
GEP20105074B (en) 2010-09-10
BRPI0620408B1 (pt) 2020-09-15
WO2007071752A3 (en) 2007-11-08
SMP200800041B (it) 2009-07-14
JP5153645B2 (ja) 2013-02-27
EP1976847A2 (en) 2008-10-08
BRPI0620408A2 (pt) 2011-11-08
WO2007071752A2 (en) 2007-06-28
ME00011A (me) 2009-02-10
SMAP200800041A (it) 2008-07-23
AU2006326989A1 (en) 2007-06-28
ZA200805092B (en) 2009-09-30
AU2006326989B2 (en) 2011-11-24
US20080312248A1 (en) 2008-12-18
MEP3808A (xx) 2010-02-10
MA30063B1 (fr) 2008-12-01
CA2634047C (en) 2016-04-12
EA016438B1 (ru) 2012-05-30
ECSP088561A (es) 2008-07-30
NO20083214L (no) 2008-09-01
CN101336237A (zh) 2008-12-31
SV2008002967A (es) 2011-01-24
HN2008000949A (es) 2010-11-11
EA200801565A1 (ru) 2008-12-30
BRPI0620408B8 (pt) 2021-05-25
CA2634047A1 (en) 2007-06-28
KR20080090439A (ko) 2008-10-08
CN101336237B (zh) 2015-09-30
TNSN08276A1 (en) 2009-10-30
IL192093A0 (en) 2008-12-29
US20130030171A1 (en) 2013-01-31
EP1976847B1 (en) 2015-06-17
JP2009520768A (ja) 2009-05-28

Similar Documents

Publication Publication Date Title
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
NO20090628L (no) Pyridizinon derivativater
UY30748A1 (es) Compuesto0s novedosos
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
UY29803A1 (es) Derivados de adeninas, composiciones farmacéuticas conteniéndolos, procedimientos de preparación y aplicaciones
CY1110900T1 (el) Χημικες ενωσεις
CY1108275T1 (el) Χημικες ενωσεις
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
EA201170344A1 (ru) Азаиндольные ингибиторы iap
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
SE0403086D0 (sv) Compounds
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)